{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:23:46Z","timestamp":1790645026405,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence nationale de la recherche","doi-asserted-by":"publisher","award":["ANR-11-INBS-0006"],"award-info":[{"award-number":["ANR-11-INBS-0006"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence nationale de la recherche","doi-asserted-by":"publisher","award":["ANR-16-CE17-0011"],"award-info":[{"award-number":["ANR-16-CE17-0011"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["764458"],"award-info":[{"award-number":["764458"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.biopha.2022.113994","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T23:28:19Z","timestamp":1667950099000},"page":"113994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["[11C]glyburide PET imaging for quantitative determination of the importance of Organic Anion-Transporting Polypeptide transporter function in the human liver and whole-body"],"prefix":"10.1016","volume":"156","author":[{"given":"Sol\u00e8ne","family":"Marie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Breuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zacharias","family":"Chalampalakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Becquemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Verstuyft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Lise","family":"Lecoq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Caill\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gervais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Lebon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Comtat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Bottlaender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Tournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.113994_bib1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.pharmthera.2018.12.009","article-title":"Organic anion transporting polypeptide 2B1 \u2013 More than a glass-full of drug interactions","volume":"196","author":"McFeely","year":"2019","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.biopha.2022.113994_bib2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd4461","article-title":"What do drug transporters really do?","volume":"14","author":"Nigam","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2022.113994_bib3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2022.113994_bib4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-3659(01)00480-1","article-title":"Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney","volume":"78","author":"Kusuhara","year":"2002","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2022.113994_bib5","first-page":"1","article-title":"The role of organic anion transporting polypeptides in drug absorption, distribution, excretion and drug-drug interactions","volume":"0","author":"Kovacsics","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.biopha.2022.113994_bib6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00418-017-1580-6","article-title":"Characterization of OATP1B3 and OATP2B1 transporter expression in the islet of the adult human pancreas","volume":"148","author":"Kim","year":"2017","journal-title":"Histochem Cell Biol."},{"key":"10.1016\/j.biopha.2022.113994_bib7","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/j.1476-5381.2011.01724.x","article-title":"OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies","volume":"165","author":"Roth","year":"2012","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2022.113994_bib8","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.mam.2012.10.009","article-title":"The SLCO (former SLC21) superfamily of transporters","volume":"34","author":"Hagenbuch","year":"2013","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.biopha.2022.113994_bib9","article-title":"Prediction of pharmacokinetic drug-drug interactions causing atorvastatin-induced rhabdomyolysis using physiologically based pharmacokinetic modelling","volume":"119","author":"Li","year":"2019","journal-title":"Biomed. Pharmacother. Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2022.113994_bib10","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2165\/00003088-200342100-00002","article-title":"Whole body pharmacokinetic models","volume":"42","author":"Nestorov","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biopha.2022.113994_bib11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/cts.12448","article-title":"Importance of drug pharmacokinetics at the site of action","volume":"10","author":"Rizk","year":"2017","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.biopha.2022.113994_bib12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41573-020-0080-x","article-title":"Phase 0\/microdosing approaches: time for mainstream application in drug development?","volume":"19","author":"Burt","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2022.113994_bib13","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00259-018-4153-6","article-title":"Dynamic whole-body PET imaging: principles, potentials and applications","volume":"46","author":"Rahmim","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.biopha.2022.113994_bib14","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.pharmthera.2018.04.006","article-title":"Imaging techniques to study drug transporter function in vivo","volume":"189","author":"Tournier","year":"2018","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.biopha.2022.113994_bib15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jconrel.2020.05.020","article-title":"Focused ultrasound for opening blood-brain barrier and drug delivery monitored with positron emission tomography","volume":"324","author":"Arif","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2022.113994_bib16","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jconrel.2022.05.026","article-title":"Dose-response assessment of cerebral P-glycoprotein inhibition in vivo with [18F]MC225 and PET","volume":"347","author":"Garcia-Varela","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2022.113994_bib17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jconrel.2022.06.065","article-title":"Impact of P-gp and BCRP on pulmonary drug disposition assessed by PET imaging in rats","volume":"349","author":"Mairinger","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2022.113994_bib18","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jconrel.2006.06.009","article-title":"Role of SLC xenobiotic transporters and their regulatory mechanisms PDZ proteins in drug delivery and disposition","volume":"116","author":"Sugiura","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2022.113994_bib19","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.xphs.2017.04.031","article-title":"Imaging probes and modalities for the study of solute carrier O (SLCO)-transport function in vivo","volume":"106","author":"Marie","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2022.113994_bib20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/cpt.888","article-title":"Influence of OATPs on hepatic disposition of erlotinib measured with positron emission tomography","volume":"104","author":"Bauer","year":"2018","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.biopha.2022.113994_bib21","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/cpt.1506","article-title":"PET imaging of [11C]Rosuvastatin hepatic concentrations and hepatobiliary transport in humans in the absence and presence of cyclosporine A","volume":"106","author":"Billington","year":"2019","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.biopha.2022.113994_bib22","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1124\/dmd.118.080408","article-title":"A clinical quantitative evaluation of hepatobiliary transport of [11C]Dehydropravastatin in humans using positron emission tomography","volume":"46","author":"Kaneko","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2022.113994_bib23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.dmpk.2019.02.004","article-title":"Quantitative investigation of hepatobiliary transport of [11C]telmisartan in humans by PET imaging","volume":"34","author":"Maeda","year":"2019","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.biopha.2022.113994_bib24","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2967\/jnumed.111.098681","article-title":"PET imaging\u2013based evaluation of hepatobiliary transport in humans with (15R)-11C-TIC-Me","volume":"53","author":"Takashima","year":"2012","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.biopha.2022.113994_bib25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ogc.2017.02.002","article-title":"Gestational diabetes: diagnosis, classification, and clinical care","volume":"44","author":"Mack","year":"2017","journal-title":"Obstet. Gynecol. Clin. N. Am."},{"key":"10.1016\/j.biopha.2022.113994_bib26","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1124\/dmd.116.074815","article-title":"Transporter-mediated disposition, clinical pharmacokinetics and cholestatic potential of glyburide and its primary active metabolites","volume":"45","author":"Li","year":"2017","journal-title":"Drug Metab. Dispos. Am. Soc. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2022.113994_bib27","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/jhep.2002.34133","article-title":"Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver","volume":"36","author":"Vavricka","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2022.113994_bib28","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/clpt.2008.186","article-title":"Elucidating Rifampin\u2019s inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effect of enzyme induction and transporter inhibition for a drug and its primary metabolite","volume":"85","author":"Zheng","year":"2009","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.biopha.2022.113994_bib29","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.ejps.2012.08.017","article-title":"Steroid hormones specifically modify the activity of organic anion transporting polypeptides","volume":"47","author":"Koenen","year":"2012","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.biopha.2022.113994_bib30","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1124\/dmd.104.002337","article-title":"Citrus juices inhibit the function of human organic anion-transporting polypeptide Oatp-B","volume":"33","author":"Satoh","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2022.113994_bib31","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.nucmedbio.2019.12.008","article-title":"Automated two-step manufacturing of [11C]glyburide radiopharmaceutical for PET imaging in humans","volume":"84\u201385","author":"Caill\u00e9","year":"2020","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.biopha.2022.113994_bib32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF00257728","article-title":"Pharmacokinetics of intravenous glibenclamide investigated by a high performance liquid chromatographic assay","volume":"23","author":"Rogers","year":"1982","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2022.113994_bib33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13550-018-0434-0","article-title":"Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats","volume":"8","author":"Amor","year":"2018","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.biopha.2022.113994_bib34","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1007\/s11095-012-0776-7","article-title":"Discrepancies in the P-glycoprotein-mediated transport of (18)F-MPPF: a pharmacokinetic study in mice and non-human primates","volume":"29","author":"Tournier","year":"2012","journal-title":"Pharmaceut. Res."},{"key":"10.1016\/j.biopha.2022.113994_bib35","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/j.1552-4604.1995.tb04115.x","article-title":"Glyburide protein binding and the effect of albumin glycation in children, young adults, and older adults with diabetes","volume":"35","author":"Olsen","year":"1995","journal-title":"J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2022.113994_bib36","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1208\/s12248-013-9514-2","article-title":"Effects of selected OATP and\/or ABC transporter inhibitors on the brain and whole-body distribution of glyburide","volume":"15","author":"Tournier","year":"2013","journal-title":"AAPSJ."},{"key":"10.1016\/j.biopha.2022.113994_bib37","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1124\/dmd.114.061580","article-title":"Interspecies variability in expression of hepatobiliary transporters across human, dog, monkey, and rat as determined by quantitative proteomics","volume":"43","author":"Wang","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2022.113994_bib38","doi-asserted-by":"crossref","first-page":"680","DOI":"10.3390\/pharmaceutics3040680","article-title":"Transporter-mediated drug-drug interactions with oral antidiabetic drugs","volume":"3","author":"Klatt","year":"2011","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2022.113994_bib39","unstructured":"S. Marie, K.L. Frost, R.K. Hau, L. Martinez-Guerrero, J.M. Izu, C.M. Myers, et al., Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients, Acta Pharm. Sin. B [Internet], 2022 [cited 2022 Nov 7]; Available from: \u3008https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2211383522003690\u3009."},{"key":"10.1016\/j.biopha.2022.113994_bib40","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1128\/AAC.01151-16","article-title":"Inhibitory interaction potential of 22 antituberculosis drugs on organic anion and cation transporters of the SLC22A family","volume":"60","author":"Parvez","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2022.113994_bib41","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1128\/AAC.02765-15","article-title":"Characterization of 22 antituberculosis drugs for inhibitory interaction potential on organic anionic transporter polypeptide (OATP)-mediated uptake","volume":"60","author":"Parvez","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2022.113994_bib42","article-title":"Impact of kidney dysfunction on hepatic and intestinal drug transporters","volume":"143","author":"Dro\u017adzik","year":"2021","journal-title":"Biomed. Pharmacother. Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2022.113994_bib43","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s005920050081","article-title":"Glibenclamide: an old drug with a novel mechanism of action?","volume":"34","author":"Luzi","year":"1997","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.biopha.2022.113994_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114534","article-title":"OATP2B1 \u2013 the underrated member of the organic anion transporting polypeptide family of drug transporters?","volume":"188","author":"Kinzi","year":"2021","journal-title":"Biochem. Pharm."},{"key":"10.1016\/j.biopha.2022.113994_bib45","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/bdd.2171","article-title":"Functional characterization for polymorphic organic anion transporting polypeptides (OATP\/SLCO1B1, 1B3, 2B1) of monkeys recombinantly expressed with various OATP probes","volume":"40","author":"Takahashi","year":"2019","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.biopha.2022.113994_bib46","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1212\/WNL.0000000000007378","article-title":"11C-glyburide PET imaging unveils the negligible brain penetration of glyburide in humans","volume":"92","author":"Marie","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2022.113994_bib47","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1124\/jpet.109.160564","article-title":"Transplacental pharmacokinetics of glyburide, rhodamine 123, and BODIPY FL prazosin: effect of drug efflux transporters and lipid solubility","volume":"331","author":"Cygalova","year":"2009","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.biopha.2022.113994_bib48","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.placenta.2005.11.012","article-title":"Transport of glyburide by placental ABC transporters: implications in fetal drug exposure","volume":"27","author":"Gedeon","year":"2006","journal-title":"Placenta"},{"key":"10.1016\/j.biopha.2022.113994_bib49","doi-asserted-by":"crossref","first-page":"383.e1","DOI":"10.1016\/j.ajog.2010.01.035","article-title":"Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin","volume":"202","author":"Hemauer","year":"2010","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.biopha.2022.113994_bib50","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.placenta.2008.05.001","article-title":"The role of placental breast cancer resistance protein in the efflux of glyburide across the human placenta","volume":"29","author":"Pollex","year":"2008","journal-title":"Placenta"},{"key":"10.1016\/j.biopha.2022.113994_bib51","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1124\/mol.107.041616","article-title":"The breast cancer resistance protein (Bcrp1\/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an obstetric-fetal pharmacology research unit network and university of Washington Specialized Center of research study","volume":"73","author":"Zhou","year":"2008","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2022.113994_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.746208","article-title":"Drug transporters in the kidney: perspectives on species differences, disease status, and molecular docking","volume":"12","author":"Zou","year":"2021","journal-title":"Front. Pharm."},{"key":"10.1016\/j.biopha.2022.113994_bib53","article-title":"Challenges and perspectives of the hybridization of PET with functional MRI or ultrasound for neuroimaging","author":"Tournier","year":"2020","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopha.2022.113994_bib54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2967\/jnumed.116.184028","article-title":"Total-body PET: maximizing sensitivity to create new opportunities for clinical research and patient care","volume":"59","author":"Cherry","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.biopha.2022.113994_bib55","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/978-981-13-7647-4_6","article-title":"Roles of hepatic drug transporters in drug disposition and liver toxicity","volume":"1141","author":"Pan","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.biopha.2022.113994_bib56","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jhep.2022.01.020","article-title":"Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity","volume":"77","author":"Ghallab","year":"2022","journal-title":"J. Hepatol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222201383X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222201383X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:17:13Z","timestamp":1778242633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222201383X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":56,"alternative-id":["S075333222201383X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113994","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[11C]glyburide PET imaging for quantitative determination of the importance of Organic Anion-Transporting Polypeptide transporter function in the human liver and whole-body","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113994","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113994"}}